Douglas C. Bryant Sells 69,168 Shares of Quidel Corp. (QDEL) Stock
Quidel Corp. (NASDAQ:QDEL) CEO Douglas C. Bryant sold 69,168 shares of the firm’s stock in a transaction on Friday, September 30th. The shares were sold at an average price of $21.76, for a total transaction of $1,505,095.68. Following the completion of the sale, the chief executive officer now owns 291,121 shares in the company, valued at $6,334,792.96. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Quidel Corp. (NASDAQ:QDEL) opened at 22.09 on Friday. The firm’s market capitalization is $715.54 million. Quidel Corp. has a one year low of $13.21 and a one year high of $23.94. The stock has a 50 day moving average of $21.73 and a 200-day moving average of $19.11.
Quidel Corp. (NASDAQ:QDEL) last announced its earnings results on Wednesday, July 27th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.14. Quidel Corp. had a negative net margin of 6.59% and a negative return on equity of 1.06%. The company earned $39.10 million during the quarter, compared to analysts’ expectations of $37.98 million. During the same period last year, the company posted ($0.14) earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, equities analysts anticipate that Quidel Corp. will post ($0.14) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in QDEL. Brown Capital Management LLC boosted its position in shares of Quidel Corp. by 0.4% in the second quarter. Brown Capital Management LLC now owns 5,748,536 shares of the company’s stock valued at $102,669,000 after buying an additional 23,100 shares during the last quarter. Janus Capital Management LLC boosted its position in shares of Quidel Corp. by 1.3% in the second quarter. Janus Capital Management LLC now owns 2,265,082 shares of the company’s stock valued at $40,454,000 after buying an additional 29,825 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Quidel Corp. by 1.7% in the second quarter. Vanguard Group Inc. now owns 1,963,521 shares of the company’s stock valued at $35,069,000 after buying an additional 32,681 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Quidel Corp. by 27.7% in the second quarter. Macquarie Group Ltd. now owns 858,387 shares of the company’s stock valued at $15,331,000 after buying an additional 186,020 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in shares of Quidel Corp. by 0.9% in the second quarter. BlackRock Fund Advisors now owns 639,490 shares of the company’s stock valued at $11,421,000 after buying an additional 5,764 shares during the last quarter. Institutional investors own 94.28% of the company’s stock.
QDEL has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Quidel Corp. from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a report on Wednesday, July 13th. Canaccord Genuity restated a “hold” rating and issued a $22.00 price objective on shares of Quidel Corp. in a report on Friday, July 29th. Finally, Raymond James Financial Inc. upgraded shares of Quidel Corp. from a “market perform” rating to an “outperform” rating and set a $21.50 price objective on the stock in a report on Monday, June 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $21.58.
About Quidel Corp.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers.
Receive News & Stock Ratings for Quidel Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corp. and related stocks with our FREE daily email newsletter.